{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:45:26Z","timestamp":1791639926893,"version":"4.3.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T00:00:00Z","timestamp":1619654400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1007\/s10157-021-02068-x","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T18:02:29Z","timestamp":1619719349000},"page":"970-980","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Factors predicting decline in renal function and kidney volume growth in autosomal dominant polycystic kidney disease: a prospective cohort study (Japanese Polycystic Kidney Disease registry: J-PKD)"],"prefix":"10.1007","volume":"25","author":[{"given":"Kiyotaka","family":"Uchiyama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshio","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yosuke","family":"Shimada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saori","family":"Nishio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Kataoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiro","family":"Mitobe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazushige","family":"Hanaoka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshifumi","family":"Ubara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Suwabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinari","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kikuo","family":"Nutahara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Tsuruya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiji","family":"Ishimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinya","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadashi","family":"Sofue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ichiei","family":"Narita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoichi","family":"Maruyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeo","family":"Horie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5400-5195","authenticated-orcid":false,"given":"Satoru","family":"Muto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,29]]},"reference":[{"key":"2068_CR1","doi-asserted-by":"publisher","first-page":"919","DOI":"10.1016\/S0140-6736(18)32782-X","volume":"393","author":"E Cornec-Le Gall","year":"2019","unstructured":"Cornec-Le Gall E, Alam A, Perrone RD. Autosomal dominant polycystic kidney disease. Lancet. 2019;393:919\u201335.","journal-title":"Lancet"},{"key":"2068_CR2","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s41100-019-0248-1","volume":"5","author":"K Nitta","year":"2019","unstructured":"Nitta K, Masakane I, Hanafusa N, Taniguchi M, Hasegawa T, Nakai S, et al. Annual dialysis data report 2017, JSDT renal data registry. Ren Replace Ther. 2019;5:53.","journal-title":"Ren Replace Ther"},{"key":"2068_CR3","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/ki.1992.195","volume":"41","author":"PA Gabow","year":"1992","unstructured":"Gabow PA, Johnson AM, Kaehny WD, Kimberling WJ, Lezotte DC, Duley IT, et al. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease. Kidney Int. 1992;41:1311\u20139.","journal-title":"Kidney Int"},{"key":"2068_CR4","doi-asserted-by":"publisher","first-page":"1560","DOI":"10.1681\/ASN.V8101560","volume":"8","author":"AM Johnson","year":"1997","unstructured":"Johnson AM, Gabow PA. Identification of patients with autosomal dominant polycystic kidney disease at highest risk for end-stage renal disease. J Am Soc Nephrol. 1997;8:1560\u20137.","journal-title":"J Am Soc Nephrol"},{"key":"2068_CR5","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1053\/ajkd.2002.33379","volume":"39","author":"GM Fick-Brosnahan","year":"2002","unstructured":"Fick-Brosnahan GM, Belz MM, McFann KK, Johnson AM, Schrier RW. Relationship between renal volume growth and renal function in autosomal dominant polycystic kidney disease: a longitudinal study. Am J Kidney Dis. 2002;39:1127\u201334.","journal-title":"Am J Kidney Dis"},{"key":"2068_CR6","doi-asserted-by":"publisher","first-page":"112","DOI":"10.2215\/CJN.00910306","volume":"2","author":"VE Torres","year":"2007","unstructured":"Torres VE, King BF, Chapman AB, Brummer ME, Bae KT, Glockner JF, et al. Magnetic resonance measurements of renal blood flow and disease progression in autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2007;2:112\u201320.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2068_CR7","doi-asserted-by":"publisher","first-page":"640","DOI":"10.2215\/CJN.03250410","volume":"6","author":"VE Torres","year":"2011","unstructured":"Torres VE, Grantham JJ, Chapman AB, Mrug M, Bae KT, King BF Jr, et al. Potentially modifiable factors affecting the progression of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2011;6:640\u20137.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2068_CR8","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1007\/s10157-011-0428-y","volume":"15","author":"S Tokiwa","year":"2011","unstructured":"Tokiwa S, Muto S, China T, Horie S. The relationship between renal volume and renal function in autosomal dominant polycystic kidney disease. Clin Exp Nephrol. 2011;15:539\u201345.","journal-title":"Clin Exp Nephrol"},{"key":"2068_CR9","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1007\/s10157-012-0611-9","volume":"16","author":"E Higashihara","year":"2012","unstructured":"Higashihara E, Horie S, Muto S, Mochizuki T, Nishio S, Nutahara K. Renal disease progression in autosomal dominant polycystic kidney disease. Clin Exp Nephrol. 2012;16:622\u20138.","journal-title":"Clin Exp Nephrol"},{"key":"2068_CR10","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1159\/000045214","volume":"80","author":"E Higashihara","year":"1998","unstructured":"Higashihara E, Nutahara K, Kojima M, Tamakoshi A, Yoshiyuki O, Sakai H, et al. Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan. Nephron. 1998;80:421\u20137.","journal-title":"Nephron"},{"key":"2068_CR11","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1681\/ASN.2017070819","volume":"29","author":"KL Nowak","year":"2018","unstructured":"Nowak KL, You Z, Gitomer B, Brosnahan G, Torres VE, Chapman AB, et al. Overweight and obesity are predictors of progression in early autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2018;29:571\u20138.","journal-title":"J Am Soc Nephrol"},{"key":"2068_CR12","doi-asserted-by":"publisher","first-page":"2518","DOI":"10.1001\/jama.2014.6634","volume":"311","author":"J Coresh","year":"2014","unstructured":"Coresh J, Turin TC, Matsushita K, Sang Y, Ballew SH, Appel LJ, et al. Decline in estimated glomerular filtration rate and subsequent risk of end-stage renal disease and mortality. JAMA. 2014;311:2518\u201331.","journal-title":"JAMA"},{"key":"2068_CR13","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.kint.2017.09.027","volume":"93","author":"ASL Yu","year":"2018","unstructured":"Yu ASL, Shen C, Landsittel DP, Harris PC, Torres VE, Mrug M, et al. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease. Kidney Int. 2018;93:691\u20139.","journal-title":"Kidney Int"},{"key":"2068_CR14","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/j.ekir.2017.01.003","volume":"2","author":"RD Perrone","year":"2017","unstructured":"Perrone RD, Mouksassi MS, Romero K, Czerwiec FS, Chapman AB, Gitomer BY, et al. Total kidney volume is a prognostic biomarker of renal function decline and progression to end-stage renal disease in patients with autosomal dominant polycystic kidney disease. Kidney Int Rep. 2017;2:442\u201350.","journal-title":"Kidney Int Rep"},{"key":"2068_CR15","doi-asserted-by":"publisher","first-page":"2122","DOI":"10.1056\/NEJMoa054341","volume":"354","author":"JJ Grantham","year":"2006","unstructured":"Grantham JJ, Torres VE, Chapman AB, Guay-Woodford LM, Bae KT, King BF Jr, et al. Volume progression in polycystic kidney disease. N Engl J Med. 2006;354:2122\u201330.","journal-title":"N Engl J Med"},{"key":"2068_CR16","doi-asserted-by":"publisher","first-page":"2407","DOI":"10.1056\/NEJMoa1205511","volume":"367","author":"VE Torres","year":"2012","unstructured":"Torres VE, Chapman AB, Devuyst O, Gansevoort RT, Grantham JJ, Higashihara E, et al. Tolvaptan in patients with autosomal dominant polycystic kidney disease. N Engl J Med. 2012;367:2407\u201318.","journal-title":"N Engl J Med"},{"key":"2068_CR17","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1681\/ASN.V5122037","volume":"5","author":"S Klahr","year":"1995","unstructured":"Klahr S, Breyer JA, Beck GJ, Dennis VW, Hartman JA, Roth D, et al. Dietary protein restriction, blood pressure control, and the progression of polycystic kidney disease. Modification of Diet in Renal Disease Study Group. J Am Soc Nephrol. 1995;5:2037\u201347.","journal-title":"J Am Soc Nephrol"},{"key":"2068_CR18","doi-asserted-by":"publisher","first-page":"c18","DOI":"10.1159\/000081790","volume":"99","author":"K Nutahara","year":"2005","unstructured":"Nutahara K, Higashihara E, Horie S, Kamura K, Tsuchiya K, Mochizuki T, et al. Calcium channel blocker versus angiotensin II receptor blocker in autosomal dominant polycystic kidney disease. Nephron Clin Pract. 2005;99:c18-23.","journal-title":"Nephron Clin Pract"},{"key":"2068_CR19","doi-asserted-by":"publisher","first-page":"820","DOI":"10.2215\/CJN.02810608","volume":"4","author":"MA Cadnapaphornchai","year":"2009","unstructured":"Cadnapaphornchai MA, McFann K, Strain JD, Masoumi A, Schrier RW. Prospective change in renal volume and function in children with ADPKD. Clin J Am Soc Nephrol. 2009;4:820\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2068_CR20","doi-asserted-by":"publisher","first-page":"342","DOI":"10.7326\/0003-4819-142-5-200503010-00009","volume":"142","author":"MJ Sarnak","year":"2005","unstructured":"Sarnak MJ, Greene T, Wang X, Beck G, Kusek JW, Collins AJ, et al. The effect of a lower target blood pressure on the progression of kidney disease: long-term follow-up of the modification of diet in renal disease study. Ann Intern Med. 2005;142:342\u201351.","journal-title":"Ann Intern Med"},{"key":"2068_CR21","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1053\/j.ajkd.2009.07.018","volume":"54","author":"IH de Boer","year":"2009","unstructured":"de Boer IH, Katz R, Fried LF, Ix JH, Luchsinger J, Sarnak MJ, et al. Obesity and change in estimated GFR among older adults. Am J Kidney Dis. 2009;54:1043\u201351.","journal-title":"Am J Kidney Dis"},{"key":"2068_CR22","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1053\/j.ajkd.2005.10.006","volume":"47","author":"YP Siu","year":"2006","unstructured":"Siu YP, Leung KT, Tong MK, Kwan TH. Use of allopurinol in slowing the progression of renal disease through its ability to lower serum uric acid level. Am J Kidney Dis. 2006;47:51\u20139.","journal-title":"Am J Kidney Dis"},{"key":"2068_CR23","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1053\/j.ajkd.2008.10.044","volume":"53","author":"LD Bash","year":"2009","unstructured":"Bash LD, Erlinger TP, Coresh J, Marsh-Manzi J, Folsom AR, Astor BC. Inflammation, hemostasis, and the risk of kidney function decline in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2009;53:596\u2013605.","journal-title":"Am J Kidney Dis"},{"key":"2068_CR24","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1053\/j.ajkd.2017.06.011","volume":"71","author":"MB Lanktree","year":"2018","unstructured":"Lanktree MB, Th\u00e9riault S, Walsh M, Par\u00e9 G. HDL cholesterol, LDL cholesterol, and triglycerides as risk factors for CKD: a Mendelian randomization study. Am J Kidney Dis. 2018;71:166\u201372.","journal-title":"Am J Kidney Dis"},{"key":"2068_CR25","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1681\/ASN.2017070798","volume":"29","author":"F Kronenberg","year":"2018","unstructured":"Kronenberg F. HDL in CKD\u2014the devil is in the detail. J Am Soc Nephrol. 2018;29:1356\u201371.","journal-title":"J Am Soc Nephrol"},{"key":"2068_CR26","doi-asserted-by":"publisher","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","volume":"375","author":"K Matsushita","year":"2010","unstructured":"Chronic Kidney Disease Prognosis Consortium, Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, et al. Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis. Lancet. 2010;375:2073\u201381.","journal-title":"Lancet"},{"key":"2068_CR27","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.1001\/jama.2012.16817","volume":"308","author":"SI Hallan","year":"2012","unstructured":"Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, et al. Age and association of kidney measures with mortality and end-stage renal disease. JAMA. 2012;308:2349\u201360.","journal-title":"JAMA"},{"key":"2068_CR28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1681\/ASN.2013101138","volume":"26","author":"MV Irazabal","year":"2015","unstructured":"Irazabal MV, Rangel LJ, Bergstralh EJ, Osborn SL, Harmon AJ, Sundsbak JL, et al. Imaging classification of autosomal dominant polycystic kidney disease: a simple model for selecting patients for clinical trials. J Am Soc Nephrol. 2015;26:160\u201372.","journal-title":"J Am Soc Nephrol"},{"key":"2068_CR29","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1111\/1744-9987.12308","volume":"19","author":"Y Tsubakihara","year":"2015","unstructured":"Tsubakihara Y, Akizawa T, Iwasaki M, Shimazaki R. High hemoglobin levels maintained by an erythropoiesis-stimulating agent improve renal survival in patients with severe renal impairment. Ther Apher Dial. 2015;19:457\u201365.","journal-title":"Ther Apher Dial"},{"key":"2068_CR30","doi-asserted-by":"publisher","first-page":"23","DOI":"10.7326\/0003-4819-153-1-201007060-00252","volume":"153","author":"SC Palmer","year":"2010","unstructured":"Palmer SC, Navaneethan SD, Craig JC, Johnson DW, Tonelli M, Garg AX, et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann Intern Med. 2010;153:23\u201333.","journal-title":"Ann Intern Med"},{"key":"2068_CR31","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1007\/s10157-020-01856-1","volume":"24","author":"Y Ushio","year":"2020","unstructured":"Ushio Y, Kataoka H, Sato MA, Manabe S, Watanabe S, Akihisa T, et al. Association between anemia and renal prognosis in autosomal dominant polycystic kidney disease: a retrospective study. Clin Exp Nephrol. 2020;24:500\u20138.","journal-title":"Clin Exp Nephrol"},{"key":"2068_CR32","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1111\/nep.13407","volume":"24","author":"H Kim","year":"2019","unstructured":"Kim H, Koh J, Park SK, Kim YH, Kim Y, Ahn C, et al. Baseline characteristics of the autosomal-dominant polycystic kidney disease sub-cohort of the Korean cohort study for outcomes in patients with chronic kidney disease. Nephrology (Carlton). 2019;24:422\u20139.","journal-title":"Nephrology (Carlton)"},{"key":"2068_CR33","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1053\/j.ajkd.2018.06.028","volume":"72","author":"K Kimura","year":"2018","unstructured":"Kimura K, Hosoya T, Uchida S, Inaba M, Makino H, Maruyama S, et al. Febuxostat therapy for patients with stage 3 CKD and asymptomatic hyperuricemia: a randomized trial. Am J Kidney Dis. 2018;72:798\u2013810.","journal-title":"Am J Kidney Dis"},{"key":"2068_CR34","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/nm.3092","volume":"19","author":"I Rowe","year":"2013","unstructured":"Rowe I, Chiaravalli M, Mannella V, Ulisse V, Quilici G, Pema M, et al. Defective glucose metabolism in polycystic kidney disease identifies a new therapeutic strategy. Nat Med. 2013;19:488\u201393.","journal-title":"Nat Med"},{"key":"2068_CR35","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1681\/ASN.2015030231","volume":"27","author":"M Chiaravalli","year":"2016","unstructured":"Chiaravalli M, Rowe I, Mannella V, Quilici G, Canu T, Bianchi V, et al. 2-Deoxy-d-glucose ameliorates PKD progression. J Am Soc Nephrol. 2016;27:1958\u201369.","journal-title":"J Am Soc Nephrol"},{"key":"2068_CR36","doi-asserted-by":"publisher","first-page":"861","DOI":"10.3892\/mmr.2013.1588","volume":"8","author":"C Liu","year":"2013","unstructured":"Liu C, Zhang Y, Yuan L, Fu L, Mei C. Rosiglitazone inhibits insulin-like growth factor-1-induced polycystic kidney disease cell growth and p70S6 kinase activation. Mol Med Rep. 2013;8:861\u20134.","journal-title":"Mol Med Rep"},{"key":"2068_CR37","doi-asserted-by":"publisher","first-page":"2462","DOI":"10.1073\/pnas.1011498108","volume":"108","author":"V Takiar","year":"2011","unstructured":"Takiar V, Nishio S, Seo-Mayer P, King JD Jr, Li H, Zhang L, et al. Activating AMP-activated protein kinase (AMPK) slows renal cystogenesis. Proc Natl Acad Sci USA. 2011;108:2462\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"2068_CR38","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1093\/ndt\/gfu044","volume":"30","author":"Z Mao","year":"2015","unstructured":"Mao Z, Xie G, Ong AC. Metabolic abnormalities in autosomal dominant polycystic kidney disease. Nephrol Dial Transplant. 2015;30:197\u2013203.","journal-title":"Nephrol Dial Transplant"},{"key":"2068_CR39","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1016\/j.kint.2016.10.018","volume":"91","author":"VE Torres","year":"2017","unstructured":"Torres VE, Abebe KZ, Schrier RW, Perrone RD, Chapman AB, Yu AS, et al. Dietary salt restriction is beneficial to the management of autosomal dominant polycystic kidney disease. Kidney Int. 2017;91:493\u2013500.","journal-title":"Kidney Int"},{"key":"2068_CR40","doi-asserted-by":"publisher","first-page":"3013","DOI":"10.1681\/ASN.2006080835","volume":"17","author":"PC Harris","year":"2006","unstructured":"Harris PC, Bae KT, Rossetti S, Torres VE, Grantham JJ, Chapman AB, et al. Cyst number but not the rate of cystic growth is associated with the mutated gene in autosomal dominant polycystic kidney disease. J Am Soc Nephrol. 2006;17:3013\u20139.","journal-title":"J Am Soc Nephrol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-021-02068-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-021-02068-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-021-02068-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,11]],"date-time":"2021-08-11T18:02:28Z","timestamp":1628704948000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-021-02068-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,29]]},"references-count":40,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["2068"],"URL":"https:\/\/doi.org\/10.1007\/s10157-021-02068-x","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,29]]},"assertion":[{"value":"9 February 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Toshio Mochizuki received travel fees and honoraria for lectures from Otsuka Pharmaceutical Co. Toshio Mochizuki and Hiroshi Kataoka belong to an endowed department sponsored by Otsuka Pharmaceutical Co, Chugai Pharmaceutical Co, Kyowa Hakko Kirin Co, and JMS Co. Satoru Muto received travel fees and honoraria for lectures from Otsuka Pharmaceutical Co., Ltd. Shigeo Horie and Satoru Muto belong to an endowed department sponsored by Otsuka Pharmaceutical Co., Ltd., JENESIS Co., Ltd., Nippon Shinyaku Co., Ltd., Shokubunka Co., Ltd., and Rohto Pharmaceutical Co., Ltd..","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was conducted in accordance with the guidelines written in the Declaration of Helsinki. Ethics committees from each of the 14 institutions approved the study, and the Japanese Society of Nephrology approved the study (No. 6).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}